Journal of Immunology and Immunopathology
  • Year: 2019
  • Volume: 21
  • Issue: 2

HoBi-like Pestivirus (HoBiPeV), An Emerging Bovine Pestivirus Does Not Use Non-classical Endocytic Mechanisms for Entry into Ovine Cells

  • Author:
  • Dash Prakash Moorthy1, Niranjan Mishra2,, Semmannan Kalaiyarasu3, Sandeep K. Jhade4, Vijendra Pal Singh5
  • Total Page Count: 6
  • Page Number: 82 to 87

1Ph. D. Scholar, ICAR-National Institute of High Security Animal Diseases, Anand Nagar, Bhopal-462022, Madhya Pradesh, India

2Principal Scientist, ICAR-National Institute of High Security Animal Diseases, Anand Nagar, Bhopal-462022, Madhya Pradesh, India

3Scientist, ICAR-National Institute of High Security Animal Diseases, Anand Nagar, Bhopal-462022, Madhya Pradesh, India

4SRF, ICAR-National Institute of High Security Animal Diseases, Anand Nagar, Bhopal-462022, Madhya Pradesh, India

5Director, ICAR-National Institute of High Security Animal Diseases, Anand Nagar, Bhopal-462022, Madhya Pradesh, India

*Corresponding author email id: mishranir@rediffmail.com

Online published on 30 November, 2019.

Abstract

Bovine pestiviruses, bovine viral diarrhea virus 1 (BVDV-1) and BVDV-2 enter the bovine and ovine cells exclusively through clathrin-mediated endocytosis and not through non-classical endocytosis. However, no report is available regarding the mechanisms of entry of the emerging bovine pestivirus, HoBi-like pestivirus (HoBiPeV) that causes disease in cattle, buffaloes, sheep and goats. This study was aimed to unravel the possibility of HoBiPeV in utilizing the alternate endocytic mechanisms in establishing infection in ovine cells by inhibiting the caveolae-mediated endocytosis by a cholesterol sequestering drug, nystatin and macropinocytosis by an actin disrupting drug, cytochalasin-D. The reduction in infectivity of the HoBiPeV was found to be least (7.55% and 1.45% in nystatin and cytochalasin-D treated cells respectively) even at the highest concentration of the drugs (10 ìg/mL and 0.5 ìg/mL of nystatin and cytochalasin respectively) used for the pre-treatment of ovine cells before infection. The results of this study demonstrate that the HoBiPeV does not use the alternate endocytic pathways for entry into ovine cells similar to BVDV-1 and BVDV-2. Further studies may unravel the cellular receptors involved and main entry mechanisms of HoBiPeV in the future.

Keywords

BVDV-1, BVDV-2, HoBiPeV, Entry, Caveolae mediated endocytosis, Macropinocytosis